FCM
TSHA icon

Farallon Capital Management’s Taysha Gene Therapies TSHA Stock Holding History

Farallon Capital Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.3M Buy
+2,250,000
New +$13.3M 0.07% 57

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Farallon Capital Management's TSHA Position: Q2 2026 in Review

Farallon Capital Management opened a new position in Taysha Gene Therapies (TSHA) in Q2 2026: 2,250,000 shares worth $15.3M. The stake represents 0.07% of the portfolio and ranks #57 among its holdings.

209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Farallon Capital Management held 2,250,000 shares of Taysha Gene Therapies worth $15.3M as of Q2 2026.
  • Taysha Gene Therapies was a new Farallon Capital Management position in Q2 2026.
  • Taysha Gene Therapies made up 0.07% of Farallon Capital Management's portfolio in Q2 2026, its #57 holding.
  • 209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.